Resverlogix Corp.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RVXCF | RNXT | ABVC | NCEL | TENX | TRAW | |
|---|---|---|---|---|---|---|
| Market cap | 20.66M | 59.12M | 26.69M | 14.79M | 67.74M | 4.13M |
| P/E (TTM) | — | — | — | 4.9 | — | — |
| Forward P/E | — | -10.9 | -2.3 | -4.3 | -1.2 | -0.1 |
| Price/book | -0.2 | 6.6 | 2.5 | 2.3 | 0.8 | 2.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −25.00% | +25.24% | −64.79% | −38.31% | −73.84% | −86.70% |
| Today | 0.00% | +1.55% | +1.51% | −3.03% | −1.63% | −11.06% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RVXCF news ›Resverlogix (TSE:RVX) Hits New 12-Month Low – Should You Sell?
Posted by Mitch Edgeman on Oct 23rd, 2026 Resverlogix Corp. (TSE:RVX – Get Free Report)’s share price reached a new 52-week low on Thursday. The stock traded as low as C$0.09 and last traded at C$0.09, with a volume of 23,300 shares…
Resverlogix: clinical evidence and funding remain key stock catalysts (TSX:RVX)
Resverlogix Corp. (TSX:RVX) is in focus for investors assessing biopharmaceutical research and the company’s ability to convert its strategy into measurable operating and financial progress. The main near-term questions are whether…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- kalkine.ca1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.